Acadia Pharmaceuticals (ACAD) announced that the U.S. District Court for the District of Delaware ruled in favor of Acadia regarding its ‘721 formulation patent for Nuplazid, the company’s drug for the treatment of Parkinson’s disease psychosis. The court ruled in favor of Acadia on both infringement and validity arguments in its formulation patent litigation against Aurobindo Pharma Limited and other abbreviated new drug application filers, Acadia said in a statement “We are very pleased with today’s decisive ruling in our favor, which provides patent protection for NUPLAZID 34 mg capsule formulation into 2038 This result highlights Acadia’s dedication to safeguarding our advancements in therapies for conditions with significant unmet medical needs,” said Catherine Owen Adams, Chief Executive Officer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- ACADIA Pharmaceuticals: Strengthened Patent Position and Growth Prospects Drive Buy Rating
- Acadia Pharmaceuticals price target raised to $19 from $17 at Oppenheimer
- Acadia Nuplazid patent ruling removes ‘key overhang,’ says BMO Capital
- Acadia Pharmaceuticals price target raised to $30 from $27 at Needham
- ACADIA Pharmaceuticals: Buy Rating Affirmed Amid Legal Victory and Promising R&D Prospects